Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Sep 22;13(9):2313.
doi: 10.3390/biomedicines13092313.

Human Stem Cells in Disease Modelling and Treatment: Bridging the Gap Between Bench and Bedside

Alvaro Plaza Reyes  1 , Sofia M Calado  2
Affiliations
Editorial

Human Stem Cells in Disease Modelling and Treatment: Bridging the Gap Between Bench and Bedside

Alvaro Plaza Reyes et al. Biomedicines. .

Abstract

Human stem cell research is entering a stage where disease modeling, translational applications, and clinical therapies are increasingly connected. This editorial provides an overview of the contributions included in this Special Issue, titled "Human Stem Cells in Disease Modelling and Treatment", placing them within the wider landscape of stem cell science. We summarize advances in ovarian stem cells for infertility, mesenchymal stem cells for neurodegeneration, pluripotent stem cell-derived cardiovascular and kidney organoids, adipose-derived stem cells, and emerging immunomodulatory and neural progenitor approaches. These studies illustrate the breadth of stem cell research and its potential to inform clinical practice. At the same time, challenges remain in reproducibility, safety, scalability, and ethical oversight. Looking forward, collaborative work and harmonized global standards will be important to bring laboratory findings into therapies that are safe, effective, and accessible. This editorial closes the first edition of the Special Issue with a reflection on current progress and directions for the future.

Keywords: biomanufacturing; cell therapy; clinical translation; disease modeling; ethical guidelines; human stem cells; induced pluripotent stem cells; mesenchymal stem cells; organoids; regenerative medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell. 2007;131:861–872. doi: 10.1016/j.cell.2007.11.019. - DOI - PubMed
    1. Clevers H. Modeling Development and Disease with Organoids. Cell. 2016;165:1586–1597. doi: 10.1016/j.cell.2016.05.082. - DOI - PubMed
    1. Shi Y., Inoue H., Wu J.C., Yamanaka S. Induced Pluripotent Stem Cell Technology: A Decade of Progress. Nat. Rev. Drug Discov. 2017;16:115–130. doi: 10.1038/nrd.2016.245. - DOI - PMC - PubMed
    1. Lancaster M.A., Knoblich J.A. Organogenesis in a Dish: Modeling Development and Disease Using Organoid Technologies. Science. 2014;345:1247125. doi: 10.1126/science.1247125. - DOI - PubMed
    1. Revah O., Gore F., Kelley K.W., Andersen J., Sakai N., Chen X., Li M.Y., Birey F., Yang X., Saw N.L., et al. Maturation and Circuit Integration of Transplanted Human Cortical Organoids. Nature. 2022;610:319–326. doi: 10.1038/s41586-022-05277-w. - DOI - PMC - PubMed

Publication types

LinkOut - more resources